Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FDA Rejects Teva - MedinCell's Schizophrenia Candidate

  • Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) U.S. affiliate and MedinCell SA (OTC:MDCLF) have received FDA Complete Response Letter (CRL) regarding TV-46000/mdc-IRM for schizophrenia.
  • The drug candidate is risperidone extended-release injectable suspension for subcutaneous use.
  • Teva is reviewing its next steps based on the letter and will work closely with FDA to address their recommendations.
  • Related: Teva Reports Encouraging Data From Late-Stage Schizophrenia Trial.
  • The application included Phase 3 data from two pivotal studies that evaluated the efficacy, long-term safety, and tolerability of TV-46000 as a treatment for patients with schizophrenia.
  • Price Action: TEVA shares are down 4.42% at $9.73 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.